Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course

In peptide receptor radionuclide therapy (PRRT), the bone marrow (BM) is one of the dose-limiting organs. The accepted dose limit for BM is 2 Gy, adopted from (131)I treatment. We investigated the incidence and duration of haematological toxicity and its risk factors in patients treated with PRRT wi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of nuclear medicine and molecular imaging 2016-03, Vol.43 (3), p.453
Hauptverfasser:	Bergsma, Hendrik, Konijnenberg, Mark W, Kam, Boen L R, Teunissen, Jaap J M, Kooij, Peter P, de Herder, Wouter W, Franssen, Gaston J H, van Eijck, Casper H J, Krenning, Eric P, Kwekkeboom, Dik J
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Bone Marrow - radiation effects Female Humans Iodine - chemistry Lutetium - chemistry Male Middle Aged Netherlands Neuroendocrine Tumors - mortality Neuroendocrine Tumors - radiotherapy Octreotide - adverse effects Octreotide - analogs & derivatives Octreotide - chemistry Organometallic Compounds - adverse effects Organometallic Compounds - chemistry Prognosis Prospective Studies Radiation Injuries - etiology Radiation Injuries - prevention & control Radioisotopes - adverse effects Radioisotopes - chemistry Radiometry Radiopharmaceuticals - therapeutic use Receptors, Peptide - chemistry Risk Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!